Use of Injectable Antipsychotics in Prepuberal Patients: Experience with an Atypical Case of Behavioral Disruption with Microdeletion 18p11.32-18p11.31
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Revista de Psiquiatría Infanto-Juvenil
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
DOI:
https://doi.org/10.31766/revpsij.v41n2a4Keywords:
long-acting injection antipsychotic, children, prepuberal, conduct disorder, microdelectionAbstract
The use of long-acting injectable antipsychotics in the pediatric and adolescent population has emerged as a therapeutic approach of increasing importance in the treatment of psychotic and behavioral disorders in children and adolescents in recent years. However, due to the unique characteristics of this population, which limit the performance of large-scale studies, the available information remains limited. Nevertheless, case studies have provided valuable descriptions of their use in a variety of psychiatric disorders. In this context, we present the case of a 12-year-old male with severe behavioral disturbances who simultaneously exhibited a rare microdeletion on chromosome 18p11.32-18p11.31. In the article, we detail his clinical evolution and treatment with long-acting aripiprazole, shedding light on the applicability of this formulation in complex clinical situations.
Downloads
References
Baeza I, Fortea A, Ilzarbe D, Sugranyes G. What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review. Paediatr Drugs. 2023 Mar;25(2): 135-49. https://doi.org/10.1007/s40272-023-00558-x. DOI: https://doi.org/10.1007/s40272-023-00558-x
García S, Martínez-Cengotitabengoa M, López-Zurbano S, Zorrilla I, López P, Vieta E, González-Pinto A. Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review. J Clin Psychopharmacol. 2016 Aug;36(4):355-71. https://doi.org/10.1097/JCP.0000000000000523 DOI: https://doi.org/10.1097/JCP.0000000000000523
Arango C, Baeza I, Bernardo M, Cañas F, de Dios C, Díaz-Marsá M, García-Portilla MP, Gutiérrez-Rojas L, Olivares JM, Rico-Villademoros F, Rodríguez-Jiménez R, Sánchez-Morla EM, Segarra R, Crespo-Facorro B. Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. Rev Psiquiatr Salud Ment (Engl Ed). 2019 Apr-Jun;12(2):92-105. English, Spanish. doi: 10.1016/j.rpsm.2018.03.006. Epub 2018 Jun 25. PMID: 29954707. DOI: https://doi.org/10.1016/j.rpsmen.2018.03.004
Modesitt T, Kubascik E, Ott C. Extent of use of long-acting injectable antipsychotics in children and adolescents within Indiana Medicaid. Ment Health Clin. 2018 Aug 30;8(5):202-7. https://doi.org/10.9740/mhc.2018.09.202. PMID: 30206502; PMCID: PMC6125120. DOI: https://doi.org/10.9740/mhc.2018.09.202
Cortes Morales B. Síndrome metabólico y antipsicóticos de segunda generación. Rev. Asoc. Esp. Neuropsiq. 2011;31(2): 303-20. https://doi.org/10.4321/S0211-57352011000200009. DOI: https://doi.org/10.4321/S0211-57352011000200009
Moon, E., Kim, E. and Williams, A. (2023) ‘Initiation of aripiprazole lauroxil long-acting injectable in adolescents during hospitalization: A case series’, Journal of Child and Adolescent Psychopharmacology [Preprint]. https://doi.org/10.1089/cap.2023.0049. DOI: https://doi.org/10.1089/cap.2023.0049
Alberto Verrotti, Chiara Palka, Giovanni Prezioso, Melissa Alfonsi, Giuseppe Calabrese, Giandomenico Palka, Francesco Chiarelli; Deletion 18p11.32p11.31 in a Child with Global Developmental Delay and Atypical, Drug-Resistant Absence Seizures. Cytogenet Genome Res 1 September 2015;146(2): 115-9. https://doi.org/10.1159/000438502 DOI: https://doi.org/10.1159/000438502
Lytle S, McVoy M, Sajatovic M. Long-Acting Injectable Antipsychotics in Children and Adolescents. J Child Adolesc Psychopharmacol. 2017 Feb;27(1): 2-9. https://doi.org/10.1089/cap.2016.0055 DOI: https://doi.org/10.1089/cap.2016.0055
Potkin SG, Preda A. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy. 2016;17(3): 395-407. https://doi.org/10.1517/14656566.2015.1114100. DOI: https://doi.org/10.1517/14656566.2015.1114100
© 2021 AEPNyA Todos los derechos reservados
